UNICREDIT BANK/CALL/VERTEX PHARMACEUTICALS/550/0.1/18.06.25 | Real-time BOERSE MUENCHEN 05:41:03 2024-06-05 EDT | ||
| 3.55 EUR | 0.00% |
|
| Current month | +23.26% | ||
| 1 month | +141.50% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-06-05 | 3.55 | 0.00% |
| 24-06-04 | 3.55 | +11.64% |
| 24-06-03 | 3.18 | +10.42% |
| 24-05-31 | 2.88 | +16.60% |
| 24-05-30 | 2.47 | -2.37% |
Real-time BOERSE MUENCHEN
Last update June 05, 2024 at 05:41 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
UniCredit
|
| WKN | HC7U37 |
| ISIN | DE000HC7U375 |
| Date issued | 2023-06-30 |
| Strike | 550 $ |
| Maturity | 2025-06-18 (379 Days) |
| Parity | 10 : 1 |
| Emission price | 2.25 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.95 € |
|---|---|
| Lowest since issue | 1.09 € |
| Spread | 0.14 € |
| Spread % | 3.86% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
475
USD
Average target price
463.5
USD
Spread / Average Target
-2.41%
- Stock Market
- Warrants
- Warrant
